Vitiligo

 

Below is a list of our vitiligo studies that are currently enrolling.

A Phase 3 Randomized, Double-Blind, 52-Week Placebo-Controlled, Multi-Center Study Investigating The Efficacy, Safety, and Tolerability of Ritlecitinib In Adult And Adolescent Participants With Non Segmental Vitiligo 

 

• Population: Adult participants ≥18 years of age with non-segmental vitiligo
• Study Condition: Non-segmental vitiligo, both active and stable, in participants with a diagnosis for at least 3 months with inclusive body surface area involvement of 4%-60% and body surface area ≥0.5% involvement on the face
• Study Design: This study is a phase 3 randomized, double-blind, placebo-controlled, multi-center study investigating the efficacy, safety, and tolerability of Ritlecitinib in adult participants with non-segmental vitiligo. Participants will be randomized to receive a daily set dose of the oral investigational drug Ritlecitinib, 50 mg or its corresponding placebo.
  • Arm 1: Ritlecitinib 50mg
  • Arm 2: Placebo
• Duration: 52 weeks
• Compensation is provided for participation
• Study is currently enrolling

Daily Topical Rapamycin Therapy for the Treatment of Vitiligo (Non-Segmental Type)

• Population: Patients aged 12 years and older
• Study Condition: Non-segmental vitiligo
• Study Design: This is a research study to learn whether topical rapamycin is safe and effective in patients with non-segmental type vitiligo when applied topically once daily. The study duration is 9 months. At the enrollment visit and during follow up visits, participants will have photos of the lesion(s) taken and complete questionnaires regarding quality of life and side effects experienced.
• There will be a total of $50 compensation to participants paid in $10 installments over the course of 5 visits
• Compensation will be provided

 

Email: linkousc@musc.edu